Poisson process factorization for mutational signature analysis with genomic covariates

Alessandro Zito, Giovanni Parmigiani, Jeffrey W. Miller · 2025

Read Poisson process factorization for mutational signature analysis with genomic covariates by Alessandro Zito, Giovanni Parmigiani, Jeffrey W. Miller (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2510-26090.txt.

Introduction

Alessandro Zito, Giovanni Parmigiani, and Jeffrey W. Miller model how mutation processes leave their marks along a cancer genome. Each mutational process, from exposures to faulty repair, produces a signature, a characteristic mix of mutation types at set rates. Standard methods factor a matrix of mutation counts from many tumors to infer signatures, but they ignore how mutation rates vary along the genome with local features.

Their Poisson process factorization lets each patient exposure vary by position, driven by genomic covariates and patient specific copy numbers through a log linear model. Covariates include histone marks, replication timing, and nucleosome position. They apply the method to one hundred thirteen breast tumors with over seven hundred thousand mutations.

Catalog record

CREATORAlessandro Zito, Giovanni Parmigiani, Jeffrey W. Miller
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE113 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2510-26090

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Poisson process factorization for mutational signature analysis with genomic covariates Alessandro Zito, Giovanni Parmigiani, Jeffrey W. Miller Abstract Mutational signatures are powerful summaries of the mutational processes altering the DNA of cancer cells and are increasingly relevant as biomarkers in personalized treatments. The widespread approach to mutational signature analysis consists of decomposing the matrix of mutation counts from a sample of patients via non-negative matrix factorization ( nmf ) algorithms. However, by working with aggregate counts, this procedure ignores the non-homogeneous patterns of occurrence of somatic mutations along the genome, as well as the tissue-specific characteristics that notoriously influence their rate of appearance. This gap is primarily due to a lack of adequate methodologies to leverage locus-specific covariates in the factorization directly. In this paper, we address these limitations by introducing a model based on Poisson point processes to infer mutational signatures and their activities as they vary across genomic regions. Using covariate-dependent factorized intensity functions, our Poisson process factorization ( ppf ) generalizes the baseline nmf model to include regression coefficients that capture the effect of commonly known genomic features on the mutation rates from each latent process. Furthermore, our method relies on sparsity-inducing hierarchical priors to automatically infer the number of active latent factors in the data, avoiding the need to fit multiple models for a range of plausible ranks. We present algorithms to obtain maximum a posteriori estimates and uncertainty quantification via Markov chain Monte Carlo. We test the method on simulated data and on real data from breast cancer, using covariates on alterations in chromosomal copies, histone modifications, cell replication timing, nucleosome positioning, and DNA methylation. Our results shed light on the joint effect that epigenetic marks have on the latent processes at high resolution. Keywords: Cancer genomics; Latent factor models; Mutational signatures analysis; Non-negative matrix factorization; Poisson point processes. 1 Introduction 1.1 Motivation Cancer is associated with the progressive accumulation of mutations in the genome of the somatic cells of the body ( Stratton et al. 2009 ) . These mutations manifest in distinctive patterns called mutational signatures , which are latent vectors encoding the probability of various mutation types ( Nik-Zainal et al. 2012 ; Nik-Zainal et al. 2016 ; Alexandrov et al. 2013 ; Kucab et al. 2019 ) . Each signature represents a specific biological process, such as failures in the DNA repair mechanisms, oxidative stress, or exposures to exogenous carcinogens like tobacco smoking or ultraviolet light. Crucially, their correct identification in patients has led to several improvements in precision therapies ( Aguirre et al. 2018 ; Gulhan et al. 2019 ; Samur et al. 2020 ) , making mutational signature analysis a recent milestone in cancer research ( Alexandrov et al. 2020 ) . Refer to Koh et al. 2021 for an overview, and to the Catalogue of Somatic Mutations in Cancer ( Tate et al. 2018 , cosmic ;) for a curated collection of signatures and their etiology across multiple tumors and environmental agents. Somatic mutations are identified by comparing genomes from cancer cells against those from healthy cells in the same tissue using next-generation sequencing technologies and variant calling algorithms ( Benjamin et al. 2019 ) . This process returns both the mutation type —for instance, a C > T single-base substitution ( sbs )—and its genomic coordinate , that is, the position of the mutation within a chromosome. Subsequently, one applies dimensionality reduction methods, such as non-negative matrix factorization ( Lee and Seung 1999 ; Alexandrov et al. 2013 ) or the hierarchical Dirichlet process ( Teh et al. 2006 ; Martínez-Ruiz et al. 2023 ) , to the matrix of mutation counts obtained from patients with similar diagnoses. Then, the inferred signatures are compared with the cosmic catalog to shed light on the underlying biological processes at play. Such a pipeline is advantageous in being agnostic to the specificity of the tumor under investigation, which has favored abundant development of methods and software to streamline inference, both for single-study ( Fischer et al. 2013 ; Rosales et al. 2016 ; Kim et al. 2016 ; Blokzijl et al. 2018 ; Wang et al. 2020 ; Li et al. 2020 ; Islam et al. 2022 ; Pandey et al. 2022 ; Díaz-Gay et al. 2023 ; Liu et al. 2023 ; Drummond et al. 2023 ; Jin et al. 2024 ; Pancotti et al. 2024 ; Landy et al. 2025 ) and multi-study settings ( Grabski et al. 2025 ; Hansen et al. 2025 ) . Figure 1: (a) Number of single-base substitutions one-megabase bins in the ICGC Breast-AdenoCA data. Alternating colored bands and numbers indicate chromosomes. (b) Top: number of mutations 2 kilobase bins for region chrX:88,000,001-89,000,000, highlighted by the red point. Bottom: average fold change signal in the same bins for histone modification H3K9me3, in breast epithelium tissue ( encode file ENCFF764JHZ.bigWig ). However, the vast majority of the aforementioned tools operate at an aggregate scale and learn mutational signatures by considering only the total number of mutations detected along the genome of each patient. This comes with two fundamental limitations. First, modeling aggregate counts implicitly entails a constant rate of mutation across genomic regions, and such a simplifying assumption is rarely met in practice. This is evident from Figure 1 (a), which displays the number of single-base substitutions ( sbs ) in one-megabase-wide bins from 113 breast cancer patients. While many regions feature around 200 mutations, many others show either heavily inflated or depleted counts. Second, the topography of the genome—namely the collection of epigenetic modifications determining its spatial and functional arrangements—is ignored in the factorization, thus hiding the important regulatory mechanisms that impact the mutational landscape in cancer. Indeed, it has been well observed that epigenetic marks deeply influence mutation occurrences at various resolutions ( Makova and Hardison 2015 ; Supek and Lehner 2019 ) . For instance, histone modification H3K9me3 can account for nearly 40% of the variation in mutation rate at the megabase scale in many tumors ( Schuster-Böckler and Lehner 2012 ) , while early replicating euchromatin is less prone to mutations due to preferential mismatch repair functions ( Supek and Lehner 2015 ; Li et al. 2013 ) . Moreover, tumors like breast cancer often feature alterations in the number of chromosomal copies, which lead to catastrophic dysregulations of cell functions and variation in mutation occurrences ( Shahrouzi et al. 2024 ) . Figure 1 (b) shows an example where the number of mutations falling into 2-kilobase bins correlates with the signal from H3K9me3, calculated as average fold-change with respect to a baseline value from a ChIP-seq assay. The goal of this work is to introduce a model where mutational signatures and their activities are inferred from the local genomic characteristics associated with each detected mutation. We provide details on the covariates used in this paper in the next section. Then, in Section 1.3 , we describe current tools in the literature to assess the relationship between mutational signatures and these covariates. Our improvements and methodological contributions are discussed in Section 1.4 . 1.2 Overview of genomic covariates Cellular activity is regulated by the interaction between the genome and the epigenome , where epi - is a Greek prefix meaning

Read the complete text